News stories about Cogentix Medical (NASDAQ:CGNT) have been trending somewhat positive recently, Accern Sentiment reports. The research firm scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Cogentix Medical earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned press coverage about the medical device company an impact score of 45.7381761846622 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

CGNT has been the subject of several research analyst reports. Roth Capital initiated coverage on shares of Cogentix Medical in a report on Wednesday, November 8th. They issued a “buy” rating and a $4.00 price objective for the company. Aegis initiated coverage on shares of Cogentix Medical in a report on Friday. They issued a “buy” rating and a $4.75 price objective for the company. TheStreet upgraded shares of Cogentix Medical from a “d+” rating to a “c” rating in a report on Thursday, November 9th. Zacks Investment Research lowered shares of Cogentix Medical from a “buy” rating to a “hold” rating in a report on Tuesday, October 3rd. Finally, JMP Securities initiated coverage on shares of Cogentix Medical in a report on Friday, October 6th. They issued an “outperform” rating and a $5.00 price objective for the company. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. Cogentix Medical currently has an average rating of “Buy” and an average target price of $4.06.

Cogentix Medical (CGNT) traded up $0.19 during mid-day trading on Monday, hitting $3.05. 180,700 shares of the stock traded hands, compared to its average volume of 62,524. Cogentix Medical has a 1 year low of $1.55 and a 1 year high of $3.26.

ILLEGAL ACTIVITY NOTICE: “Somewhat Favorable Press Coverage Somewhat Unlikely to Affect Cogentix Medical (CGNT) Stock Price” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/12/04/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-cogentix-medical-cgnt-stock-price.html.

Cogentix Medical Company Profile

Cogentix Medical, Inc is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB).

Insider Buying and Selling by Quarter for Cogentix Medical (NASDAQ:CGNT)

Receive News & Stock Ratings for Cogentix Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogentix Medical Inc. and related stocks with our FREE daily email newsletter.